Key result
High serum thrombomodulin levels in soft tissue sarcoma patients were associated with worse 5-year metastasis-free survival compared to low levels.
Why the study?
Soluble thrombomodulin is involved in anticoagulation and related to metastasis, but its correlation with clinicopathological parameters in soft tissue tumors required clarification.
Does high serum thrombomodulin predict metastasis and poor prognosis in patients with soft tissue sarcomas?
Observational (n=135)
Does high serum thrombomodulin predict metastasis and poor prognosis in patients with soft tissue sarcomas?
High levels of soluble thrombomodulin may serve as a significant predictor of metastasis and poor prognosis in patients with soft tissue sarcomas.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for thrombomodulin as prognostic marker in soft tissue sarcoma; should not yet change practice.
BACKGROUND: Thrombomodulin (TM) has multiple biological functions and modulates not only anti-coagulation, but also cell proliferation, adhesion, and anti-inflammation activities. The main function of TM is to activate the anticoagulant pathway of protein C. Soluble TM is related to metastasis by its inactivation of thrombin. OBJECTIVES: To clarify the correlation between serum TM levels and clinicopathological parameters. METHODS: The plasma TM levels (FU/ml) of 135 primary soft tissue tumors (benign, 67; soft tissue sarcoma (STS), 68) were measured before biopsy or treatment. TM levels were analyzed and compared to various clinicopathological parameters. Log-rank test and Cox proportional analysis were used to evaluate recurrence-free survival, metastasis-free survival, and overall survival. RESULTS: STS tumors had significantly higher TM values (15.9) than benign tumors (13.7) (p= 0.0138). 5-year MFS was 81.1% in low TM and 40.0% in high TM (p= 0.00671), and 5-year OS was 85.5% in low and 52.5% in high TM in grades 1-3 (p= 0.0673). In multivariate COX proportional analysis, high-TM showed a significant difference (MFS: HR 4.37, p= 0.0147; OS: HR 3.60, p= 0.0557) in grades 1-3. CONCLUSIONS: We demonstrated that a high level of soluble TM has the potential to be a significant predictor of metastasis and poor prognosis in STS patients. TM is a candidate molecular marker for high metastatic potential and can be clinically useful for guiding therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Asanuma et al. (2019) conducted an observational in Soft tissue sarcomas (n=135). High serum thrombomodulin levels vs. Low serum thrombomodulin levels was evaluated on 5-year metastasis-free survival (HR 4.37, p=0.0147). High serum thrombomodulin levels in soft tissue sarcoma patients were associated with worse 5-year metastasis-free survival compared to low levels.
Synapse has enriched 10 related papers. Consider them for comparative context: